News Category
VERAXA Biotech's appointment of Dr. Christoph Erkel as Chief Scientific Officer signals a strategic push to advance its BiTAC® T-cell engager platform...
Quantum BioPharma's Lucid-MS, a first-in-class PAD2 inhibitor, moves toward a Phase 2 trial in multiple sclerosis after FDA clearance of its IND appli...
Quantum BioPharma receives FDA clearance for a phase 2 trial of Lucid-MS, a first-in-class multiple sclerosis drug designed to shield and potentially ...
Quantum BioPharma's Lucid-MS, the first drug designed to protect and rebuild myelin, receives FDA clearance for a Phase 2 trial, offering new hope for...
Helus Pharma CEO Michael Halstead will participate in a fireside chat at the Morgan Stanley 24th Annual Global Healthcare Conference, highlighting the...
Onco-Innovations' CMO discussed the company's lead drug candidate ONC010, a novel PNKP inhibitor with dual selectivity mechanisms, and its planned fir...
Quantum BioPharma's FDA clearance of its IND for Lucid-MS, a first-in-class non-covalent PAD2 inhibitor, enables a Phase 2 trial in multiple sclerosis...
American Fusion advances its Texatron fusion program into active testing with peak pressures of 100,000 atmospheres, signaling progress toward commerc...
Kairos Pharma's CEO will present at the H.C. Wainwright conference, underscoring the company's clinical advancements in targeting CD105 to reverse dru...
Nutriband's CEO participation in the Nasdaq LaB Biotech Summit underscores the company's strategic efforts to advance its abuse-deterrent fentanyl pat...
Silo Pharma's participation in the IPAC-RS forum underscores its commitment to advancing SPC-15, a nose-to-brain drug delivery system for PTSD, backed...
Quantum BioPharma's Lucid-MS, a novel myelin repair candidate for multiple sclerosis, received FDA clearance for Phase 2 trials, marking a significant...
Quantum BioPharma's Lucid-MS, a first-in-class myelin-protective multiple sclerosis drug candidate, has received FDA clearance to begin a Phase 2 clin...
Helus Pharma's CEO participation in a key investment conference underscores the company's advancing clinical programs and its potential to reshape men...
GeoVax supports the new global mpox vaccine stockpile and emphasizes its GEO-MVA candidate's readiness to contribute to a diversified vaccine supply f...
Voyageur Pharmaceuticals advances its iodine production feasibility study with Bayer, receiving a $1 million milestone payment, highlighting progress ...
Greenland Mines (GRML) announces a Q4 biotech spin-off and key milestones, including Nasdaq compliance and the Sarfartoq acquisition, as it transition...
VERAXA Biotech's appointment of seasoned financial executive Raju Willener as CFO signals a strategic move to bolster its capital strategy and advance...
Scinai Immunotherapeutics refocuses its R&D portfolio after terminating a license agreement, prioritizing its NanoAb platform and CDMO business to enh...
Onco-Innovations is advancing its oncology pipeline by securing manufacturing capabilities, IND-enabling activities, partnerships, and funding, markin...
OS Animal Health's presentation at the Moody Capital conference highlights its strategic push to advance OST-HER2 for canine osteosarcoma, underscorin...
Quantum BioPharma's FDA clearance for a Phase 2 trial of Lucid-MS, a first-in-class remyelinating agent, marks a pivotal step toward potentially treat...
Quantum BioPharma's FDA clearance to test Lucid-MS in phase 2 trials marks a potential breakthrough in MS treatment by targeting myelin repair, not ju...
NanoViricides has registered its Phase II Ebola trial for NV-387 Oral Gummies in the DRC, marking a significant step in developing a broad-spectrum an...
Greenland Mines announced a Q4 2026 biotech spin-off and completed the Sarfartoq acquisition, with a high-case NPV of $2.05B, positioning itself as a ...
Quantum BioPharma has received FDA clearance to begin a Phase 2 trial of its investigational multiple sclerosis drug Lucid-MS, marking a critical step...
Quantum BioPharma's FDA clearance to begin a Phase 2 trial of Lucid-MS, a first-in-class PAD2 inhibitor targeting demyelination in MS, marks a pivotal...
Quantum BioPharma's FDA clearance for Lucid-MS Phase 2 trial marks a significant step toward a targeted therapy for multiple sclerosis, potentially sh...
The LGL Group's participation in the Moody Capital conference highlights its strategic focus on critical technologies and disciplined capital allocati...
Interlink Electronics, a leader in sensors and printed electronics, will present at the Moody Capital conference, highlighting its growth strategy and...
The Moody Capital Solutions 2026 Disruptive Growth & Life Sciences Conference is set for September 9-10, offering investors a timely opportunity to ex...
Tonix Pharmaceuticals promotes Thomas Englese to Chief Commercial Officer to lead commercial operations for its fibromyalgia treatment TONMYA, signali...
AcroMeta Group Limited has entered a non-binding term sheet with Macro HRD SG Pte. Ltd. to acquire a strategic stake in Macro-ATCLS Pte. Ltd., gaining...
Onco-Innovations reports significant progress in developing ONC010, a PNKP inhibitor for cancer therapy, including high-purity manufacturing and plans...
VERAXA Biotech's appointment of seasoned financial leader Raju Willener as CFO underscores its commitment to advancing its BiTAC(R) platform and oncol...
BioVersys will showcase its antibacterial pipeline at the H.C. Wainwright conference, highlighting progress in addressing antimicrobial resistance.
OS Therapies' participation in the Moody Capital conference comes as the company anticipates key FDA and U.K. regulatory decisions for its lead candid...
A Swiss-led preclinical study reveals that administering immunotherapy before surgery significantly improves glioblastoma treatment outcomes, potentia...
Tonix Pharmaceuticals' participation in the Cantor conference underscores its strategic focus on advancing treatments for CNS disorders and immunology...
NurExone Biologic will showcase its exosome-based therapeutic platform and U.S. expansion plans at a prestigious conference, highlighting its progress...
CNS Pharmaceuticals' Chief Business Officer details the company's strategy to build a pipeline in oncology and neurology through in-licensing and acqu...
The launch of SEAM@InnoHK at Hong Kong Science Park marks a strategic move to advance sustainable development, energy, advanced manufacturing, and mat...
Quantum BioPharma's Lucid-MS candidate for progressive multiple sclerosis garners a 'Buy' rating and $8 price target from Rodman & Renshaw, underscori...
NanoViricides is advancing its measles treatment NV-387 toward a Phase II trial, leveraging FDA designations and promising animal data, as measles out...
TransCode Therapeutics' preclinical study shows its lead candidate TTX-MC138 improves survival in a breast cancer bone metastasis model, supporting it...
Oragenics provides key updates on its Phase IIa concussion trial, FDA interactions, and NYSE American compliance, underscoring its progress and hurdle...
Creative Biolabs updates its in vivo CAR-T development portfolio, offering both viral and non-viral delivery options to support researchers investigat...
Lonza's creation of the Chief Commercial Officer role and appointment of Samanta Cimitan signals a strategic push to unify customer engagement and com...
